NovaTechs, a pioneering medical technology company based in Geleen (NL), has announced its membership in Smart BioMaterials Consortium. This strategic move aligns with the company’s commitment to advancing innovative solutions in interventional radiology and cancer treatment.
Founded in 2020, NovaTechs specializes in developing advanced liquid embolic agents for treating hypervascular tumors, including those in the liver, brain, and uterine fibroids. Their flagship product, NovaSeal, offers a groundbreaking approach by transitioning from a liquid to a gel at controlled temperatures, allowing precise penetration into tumors while minimizing side effects.
By joining Smart Biomaterials Consortium, NovaTechs gains access to a robust network of experts, cutting-edge research, and collaborative opportunities within the biomaterials field. This membership is expected to accelerate the development of innovative therapies and further enhance the company’s contributions to improving cancer patient outcomes.
NovaTechs’ CEO Mohammad Nasiri commented, “Becoming part of Smart BioMaterials Consortium reinforces our mission to push the boundaries of medical innovation. This partnership will open new doors and help us bring even more advanced solutions to the market. We are more than happy to share and collaborate with other members of the ecosystem.”
For more information, visit NovaTechs.nl
